Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer
In previous clinical studies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer patients has a high risk of aggravation and mortality than in healthy infected individuals. Inoculation with coronavirus disease 2019 (COVID-19) vaccine reduces the risk of SARS-CoV-2 infec...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/44/12/400 |
| _version_ | 1797460783979823104 |
|---|---|
| author | Takuma Hayashi Kenji Sano Nobuo Yaegashi Ikuo Konishi |
| author_facet | Takuma Hayashi Kenji Sano Nobuo Yaegashi Ikuo Konishi |
| author_sort | Takuma Hayashi |
| collection | DOAJ |
| description | In previous clinical studies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer patients has a high risk of aggravation and mortality than in healthy infected individuals. Inoculation with coronavirus disease 2019 (COVID-19) vaccine reduces the risk of SARS-CoV-2 infection and COVID-19 severity. However, vaccination-induced anti-SARS-CoV-2 antibody production is said to be lower in cancer patients than in healthy individuals. In addition, the rationale for why the condition of patients with cancer worsens with COVID-19 is not well understood. Therefore, we examined the infection status of SARS-CoV-2 in the primary tumor and micrometastasis tissues of the patient with cancer and COVID-19. In this study, the expression of angiotensin-converting enzyme 2 (ACE2) was observed, and SARS-CoV-2 particles was detected in ovarian tissue cells in contact with the micrometastatic niche of the patient with high-grade serous ovarian cancer. We believe that the severity of COVID-19 in patients with cancer can be attributed to these pathological features. Therefore, the pathological findings of patients with advanced and recurrent ovarian cancer infected with SARS-CoV-2 may help decrease COVID-19 severity in patients with other cancer types. |
| first_indexed | 2024-03-09T17:11:03Z |
| format | Article |
| id | doaj.art-11f271da8ec64d07adcac5ad1799f77c |
| institution | Directory Open Access Journal |
| issn | 1467-3037 1467-3045 |
| language | English |
| last_indexed | 2024-03-09T17:11:03Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj.art-11f271da8ec64d07adcac5ad1799f77c2023-11-24T14:03:24ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452022-11-0144125879588910.3390/cimb44120400Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian CancerTakuma Hayashi0Kenji Sano1Nobuo Yaegashi2Ikuo Konishi3National Hospital Organization Kyoto Medical Centre, Kyoto 612-8555, JapanPRUM-iBio Study Group, National Hospital Organization Tokyo Headquarter, Tokyo 100-0004, JapanThe Japan Agency for Medical Research and Development (AMED), Tokyo 100-0004, JapanNational Hospital Organization Kyoto Medical Centre, Kyoto 612-8555, JapanIn previous clinical studies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer patients has a high risk of aggravation and mortality than in healthy infected individuals. Inoculation with coronavirus disease 2019 (COVID-19) vaccine reduces the risk of SARS-CoV-2 infection and COVID-19 severity. However, vaccination-induced anti-SARS-CoV-2 antibody production is said to be lower in cancer patients than in healthy individuals. In addition, the rationale for why the condition of patients with cancer worsens with COVID-19 is not well understood. Therefore, we examined the infection status of SARS-CoV-2 in the primary tumor and micrometastasis tissues of the patient with cancer and COVID-19. In this study, the expression of angiotensin-converting enzyme 2 (ACE2) was observed, and SARS-CoV-2 particles was detected in ovarian tissue cells in contact with the micrometastatic niche of the patient with high-grade serous ovarian cancer. We believe that the severity of COVID-19 in patients with cancer can be attributed to these pathological features. Therefore, the pathological findings of patients with advanced and recurrent ovarian cancer infected with SARS-CoV-2 may help decrease COVID-19 severity in patients with other cancer types.https://www.mdpi.com/1467-3045/44/12/400SARS-CoV-2COVID-19micrometastatic nichepatient with cancer |
| spellingShingle | Takuma Hayashi Kenji Sano Nobuo Yaegashi Ikuo Konishi Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer Current Issues in Molecular Biology SARS-CoV-2 COVID-19 micrometastatic niche patient with cancer |
| title | Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer |
| title_full | Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer |
| title_fullStr | Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer |
| title_full_unstemmed | Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer |
| title_short | Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer |
| title_sort | pathological evidence for residual sars cov 2 in the micrometastatic niche of a patient with ovarian cancer |
| topic | SARS-CoV-2 COVID-19 micrometastatic niche patient with cancer |
| url | https://www.mdpi.com/1467-3045/44/12/400 |
| work_keys_str_mv | AT takumahayashi pathologicalevidenceforresidualsarscov2inthemicrometastaticnicheofapatientwithovariancancer AT kenjisano pathologicalevidenceforresidualsarscov2inthemicrometastaticnicheofapatientwithovariancancer AT nobuoyaegashi pathologicalevidenceforresidualsarscov2inthemicrometastaticnicheofapatientwithovariancancer AT ikuokonishi pathologicalevidenceforresidualsarscov2inthemicrometastaticnicheofapatientwithovariancancer |